Fractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.
Shares fell 4.6% as investors reacted to cautious outlook signals, including slower-than-expected momentum in the pivotal trial enrollment and an extended timeline to top-line data, raising concerns about near-term value realization.
Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.